Another report showed that lapatinib, a dual TKI of EGFR and HER2, inhibits the nuclear transport of EGFR and HER2 and sensitizes cancer cells to fluoropyrimidine by downregulating thymidylate synthase, which is frequently overexpressed in fluoropyrimidine-resistant cancer cells [63]. Here, ERBB2 is linked to cancer.